US 11,786,503 B2
Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity
Christopher G. Armstrong, Madison, WI (US); Kevin J. Kim, Menlo Park, CA (US); Lisa Maria Lucia Pham, San Mateo, CA (US); Eunhye Park, Oakland, CA (US); Zhong Zhong, Hingham, MA (US); Guanyi Huang, Fremont, CA (US); Joseph C. Wu, Palo Alto, CA (US); Sidney Paul Elmer, Palo Alto, CA (US); Viwat Visuthikraisee, Palo Alto, CA (US); Eithon Michael G. Cadag, Seattle, WA (US); Thomas Bernard Freeman, San Bruno, CA (US); and Pek Yee Lum, Palo Alto, CA (US)
Assigned to Auransa Inc., Palo Alto, CA (US); and SCT II LLC, Naperville, IL (US)
Filed by Auransa Inc., Palo Alto, CA (US); and SCT II LLC, Naperville, IL (US)
Filed on Oct. 7, 2021, as Appl. No. 17/450,258.
Application 17/450,258 is a continuation of application No. 17/064,576, filed on Oct. 6, 2020, granted, now 11,166,936.
Application 17/064,576 is a continuation of application No. 16/737,849, filed on Jan. 8, 2020, granted, now 10,874,633, issued on Dec. 29, 2020.
Application 16/737,849 is a continuation of application No. 16/075,569, granted, now 10,806,716, issued on Oct. 20, 2020, previously published as PCT/US2017/016582, filed on Feb. 3, 2017.
Claims priority of provisional application 62/348,102, filed on Jun. 9, 2016.
Claims priority of provisional application 62/291,480, filed on Feb. 4, 2016.
Prior Publication US 2022/0133684 A1, May 5, 2022
Int. Cl. A61K 31/352 (2006.01); A61K 9/127 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01); A61K 31/136 (2006.01); A61K 31/353 (2006.01); A61K 31/4439 (2006.01); A61K 31/4545 (2006.01); A61K 31/47 (2006.01); A61K 31/496 (2006.01); A61K 31/506 (2006.01); A61K 31/517 (2006.01); A61K 31/704 (2006.01); A61K 31/7048 (2006.01); A61K 31/404 (2006.01); A61K 31/44 (2006.01); A61P 35/00 (2006.01); A61P 9/00 (2006.01); A61K 38/05 (2006.01); A61K 45/06 (2006.01); A61K 9/00 (2006.01); A61K 38/00 (2006.01)
CPC A61K 31/352 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61K 9/127 (2013.01); A61K 9/20 (2013.01); A61K 9/48 (2013.01); A61K 31/136 (2013.01); A61K 31/353 (2013.01); A61K 31/4439 (2013.01); A61K 31/4545 (2013.01); A61K 31/47 (2013.01); A61K 31/496 (2013.01); A61K 31/506 (2013.01); A61K 31/517 (2013.01); A61K 31/704 (2013.01); A61K 31/7048 (2013.01); A61K 38/005 (2013.01); A61K 38/05 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); A61K 31/404 (2013.01); A61K 31/44 (2013.01); A61P 9/00 (2018.01)] 12 Claims
 
1. A method for preventing, reducing, or eliminating cardiotoxicity induced by an anticancer agent in a subject, the method comprising administering to the subject an effective amount of a protective agent prior to or simultaneously with the anticancer agent, wherein the protective agent is myricetin or salt thereof, wherein the anticancer agent is a protein kinase inhibitor or a proteasome inhibitor, and wherein the administration of the protective agent provides an effective amount of myricetin or salt thereof in the subject, thereby preventing, reducing, or eliminating the cardiotoxicity induced by the anticancer agent.